Fig. 3From: Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisMatrix model of the proportion of patients in remission or low disease activity by CDAI at week 24/30 based on baseline SJC28, CRP, and PhGA. Data are presented as % (95% confidence interval). Predicted probability of patients in remission or low disease activity represented by shading: green, > 47.0%; yellow, 40.0–47.0%; red, < 40.0%. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; PhGA, physician global assessment; SJC28, 28 swollen joint count; VAS, visual analogue scaleBack to article page